This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Magné, N. Articles by Milano, G. Search for Related Content PubMed PubMed Citation Articles by Magné, N. Articles by Milano, G.

ZD1839 (Iressa) Modifies the Activity of Key Enzymes Linked to Fluoropyrimidine Activity

Rational Basis for a New Combination Therapy with Capecitabine

Oncopharmacology Unit, Centre Antoine Lacassagne, 06189 Nice Cedex 2 [N. M., J-L. Fi., A. D., P. F., J-L. F., C. T., N. R., S. M., M-C. E., G. M.], and Pharmacokinetics Laboratory, School of Pharmacy, 13385 Marseille Cedex 05 [J. C.], France

ABSTRACT

Purpose: The efficacy of new oral fluoropyrimidines, including capecitabine, is improved in cells expressing high levels of thymidine phosphorylase (TP) and low levels of thymidylate synthase (TS) and dihydropyrimidine dehydrogenase. We used a human head and neck cancer cell line (CAL33) to examine the influence of cell cycle modifications on TS, TP, and dihydropyrimidine dehydrogenase activity.

Experimental Design: Cells were exposed to the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 (Iressa²) and 5'-deoxy-5-fluorouridine (5'-DFUR), alone and in combination, for up to 96 h, and modifications in cell cycle, enzyme activity, and gene expression were examined.

Results: ZD1839 (24- to 72-h exposure) markedly reduced proliferation and caused a rapid increase in G₀-G₁ and a decrease in S phase; a 40-fold decrease in TS activity at 24 h and a 2.5-fold increase in TP activity at 48 h were observed. A significant link between TP activity and expression was observed (r² = 0.98; P = 0.0068). Additional investigations pointed out an increased cellular production of 5-fluorouracil anabolites from 5'-DFUR when cells were preincubated with ZD1839. Dose-effect curves of ZD1839 and 5'-DFUR, alone and in combination, were examined. Combination indices for ZD1839 + 5'-DFUR were 0.58 ± 0.1 and 0.63 ± 0.1 for 50% survival and 25% survival, respectively. Additional investigations pointed out an increased cellular production of 5-fluorouracil anabolites from 5'-DFUR when cells were preincubated with ZD1839.

Conclusions: These data demonstrate a strong synergistic interaction between ZD1839 and 5'-DFUR when ZD1839 is applied before or concurrently with 5'-DFUR. Such a drug combination would have two advantages: (a) the theoretical advantage of tumor selectivity of epidermal growth factor receptor-targeted therapy; and (b) the practical advantage of a combination therapy that could be administered p.o.

This article has been cited by other articles:

				P. Koppikar, S.-H. Choi, A. M. Egloff, Q. Cai, S. Suzuki, M. Freilino, H. Nozawa, S. M. Thomas, W. E. Gooding, J. M. Siegfried, et al. Combined Inhibition of c-Src and Epidermal Growth Factor Receptor Abrogates Growth and Invasion of Head and Neck Squamous Cell Carcinoma Clin. Cancer Res., July 1, 2008; 14(13): 4284 - 4291. [Abstract] [Full Text] [PDF]

				E. Giovannetti, C. Lemos, C. Tekle, K. Smid, S. Nannizzi, J. A. Rodriguez, S. Ricciardi, R. Danesi, G. Giaccone, and G. J. Peters Molecular Mechanisms Underlying the Synergistic Interaction of Erlotinib, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, with the Multitargeted Antifolate Pemetrexed in Non-Small-Cell Lung Cancer Cells Mol. Pharmacol., April 1, 2008; 73(4): 1290 - 1300. [Abstract] [Full Text] [PDF]

				H. Suehisa, S. Toyooka, K. Hotta, A. Uchida, J. Soh, Y. Fujiwara, K. Matsuo, M. Ouchida, M. Takata, K. Kiura, et al. Epidermal Growth Factor Receptor Mutation Status and Adjuvant Chemotherapy With Uracil-Tegafur for Adenocarcinoma of the Lung J. Clin. Oncol., September 1, 2007; 25(25): 3952 - 3957. [Abstract] [Full Text] [PDF]

				Q. S.C. Chu, G. Schwartz, J. de Bono, D. A. Smith, K. M. Koch, M. J. Versola, L. Pandite, N. Arya, J. Curtright, R. A. Fleming, et al. Phase I and Pharmacokinetic Study of Lapatinib in Combination With Capecitabine in Patients With Advanced Solid Malignancies J. Clin. Oncol., August 20, 2007; 25(24): 3753 - 3758. [Abstract] [Full Text] [PDF]

				D. Liu, Z. Liu, S. Condouris, and M. Xing BRAF V600E Maintains Proliferation, Transformation, and Tumorigenicity of BRAF-Mutant Papillary Thyroid Cancer Cells J. Clin. Endocrinol. Metab., June 1, 2007; 92(6): 2264 - 2271. [Abstract] [Full Text] [PDF]

				B. G. Czito, C. G. Willett, J. C. Bendell, M. A. Morse, D. S. Tyler, N. H. Fernando, C. R. Mantyh, G. C. Blobe, W. Honeycutt, D. Yu, et al. Increased Toxicity With Gefitinib, Capecitabine, and Radiation Therapy in Pancreatic and Rectal Cancer: Phase I Trial Results J. Clin. Oncol., February 1, 2006; 24(4): 656 - 662. [Abstract] [Full Text] [PDF]

				C.-H. Yang, C.-J. Huang, C.-S. Yang, Y.-C. Chu, A.-L. Cheng, J. Whang-Peng, and P.-C. Yang Gefitinib Reverses Chemotherapy Resistance in Gefitinib-Insensitive Multidrug Resistant Cancer Cells Expressing ATP-Binding Cassette Family Protein Cancer Res., August 1, 2005; 65(15): 6943 - 6949. [Abstract] [Full Text] [PDF]

				B. Friedmann, M. Caplin, J. A. Hartley, and D. Hochhauser Modulation of DNA Repair In vitro after Treatment with Chemotherapeutic Agents by the Epidermal Growth Factor Receptor Inhibitor Gefitinib (ZD1839) Clin. Cancer Res., October 1, 2004; 10(19): 6476 - 6486. [Abstract] [Full Text] [PDF]